Article
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Breast cancer research and treatment - 1 Nov 2020
Heeke Arielle L, Xiu Joanne, Elliott Andrew, Korn W Michael, Lynce Filipa, Pohlmann Paula R, Isaacs Claudine, Swain Sandra M, Vidal Gregory, Schwartzberg Lee S, Tan Antoinette R
Abstract excerpt
PURPOSE: Homologous recombination (HR)-deficient breast tumors may have genomic alterations that predict response to treatment with PARP inhibitors and other targeted therapies. METHODS: Comprehensive molecular profiles of 4647 breast tumors performed at Caris Life Sciences using 592-gene NGS were reviewed to identify somatic pathogenic mutations in HR genes ARID1A, ATM, ATRX, BAP1, BARD1, BLM, BRCA1/2, BRIP1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.